|Security||TKAI / Tokai Pharmaceuticals, Inc. (67011N105)|
|Institutional Shares||7,135,649 - 75.85%|
|Common Stock Shares Outstanding||9,407,024 shares (as of 2018-03-31)|
|Institutional Value||$ 17,293,000 USD|
Institutional Stock Ownership and Shareholders
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) has 18 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7,135,649 shares.
Largest shareholders include
Orbimed Advisors Llc, OrbiMed Israel BioFund GP Limited Partnership, Lifesci Index Partners Llc, Lyon Street Capital, LLC, Boxer Capital, LLC, Renaissance Technologies LLC, Vanguard Group Inc, Derby & Company, Inc, BlackRock Inc., and DRW Securities, LLC.
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|DRW Securities, LLC||12,489||15,489||24.02||51||78||52.94|
|MILLENNIUM MANAGEMENT LLC||10,158||0||-100.00||53||0||-100.00|
|VANGUARD GROUP INC||43,486||43,911||0.98||168||212||26.19|
|APPLE TREE PARTNERS II LP||784,986||13,888||-98.23|
|BANK OF AMERICA CORP /DE/||0||68||0||0|
|IFP Advisors, Inc||27||0||-100.00||0||0|
|Boxer Capital, LLC||324,383||1,635|
|UBS Group AG||3,713||2,547||-31.40||15||13||-13.33|
|Derby & Company, Inc||18,434||29,545||60.27||75||149||98.67|
|Nationwide Fund Advisors||2||0||-100.00||0||0|
|LADENBURG THALMANN FINANCIAL SERVICES INC||33||0||-100.00||0||0|
|ROYAL BANK OF CANADA||1||0||-100.00||0||0|
|OrbiMed Israel BioFund GP Limited Partnership||2,537,110||2,537,110||0.00|
|D. E. Shaw & Co., Inc.||15,679||14,879||-5.10||61||72||18.03|
|Lyon Street Capital, LLC||338,929||338,929||0.00||1,376||1,708||24.13|
|DEUTSCHE BANK AG\||4||4||0.00||0||0|
|Tower Research Capital LLC (TRC)||1,515||294||-80.59||6||1||-83.33|
|ORBIMED ADVISORS LLC||2,537,110||2,537,110||0.00||10,301||12,787||24.13|
|Lifesci Index Partners Llc||1,151,088|
|Renaissance Technologies LLC||93,276||109,876||17.80||379||554||46.17|
|MEEDER ASSET MANAGEMENT INC||1,084||755||-30.35||4||4||0.00|
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET
Financial Charts by Fintel.io
|President and CEO||Morrison Jodie Pope|
NVUS / Novus Therapeutics, Inc.|